Drug intelligence / Profile preview

gallichrome

Development stage: Unknown
Modality: Peptides, Small Molecules

Overview

Gallichrome is a synthetic peptide-based small molecule containing gallium, with the chemical formula C28H44GaN9O13 and a molecular weight of approximately 784.4 g/mol[1]. It is an experimental compound primarily used in research settings. Gallichrome directly interacts with the hydroxamate moieties of siderophores—molecules involved in iron uptake—and is utilized to study iron transport mechanisms, particularly in microbiological and biochemical research[2]. There are no approved therapeutic indications or clinical uses for gallichrome as a pharmaceutical agent.

Other names: gallichrome

Targets

FhuD (Iron(III)-hydroxamate-binding protein FhuD)

Beyond the preview

Go deeper on gallichrome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallichrome.

Explore the full profile